Diagnostic criteria for TP53-mutated myeloid disease
| BM blast % . | ICC diagnosis . | Genetic criteria . | WHO5 diagnosis . | Genetic criteria . |
|---|---|---|---|---|
| 0%-9% | MDS with mutated TP53 | Multihit TP53 mutation∗ (VAFs > 10%) or TP53 mutation and CK | MDS with biallelic TP53 inactivation | Biallelic TP53 alterations∗ |
| 10%-19% | MDS/AML with mutated TP53 | Any somatic TP53 mutation (VAF > 10%) | MDS with biallelic TP53 inactivation | Biallelic TP53 alterations∗ |
| ≥20% | AML with mutated TP53 | Any somatic TP53 mutation (VAF > 10%) |
| BM blast % . | ICC diagnosis . | Genetic criteria . | WHO5 diagnosis . | Genetic criteria . |
|---|---|---|---|---|
| 0%-9% | MDS with mutated TP53 | Multihit TP53 mutation∗ (VAFs > 10%) or TP53 mutation and CK | MDS with biallelic TP53 inactivation | Biallelic TP53 alterations∗ |
| 10%-19% | MDS/AML with mutated TP53 | Any somatic TP53 mutation (VAF > 10%) | MDS with biallelic TP53 inactivation | Biallelic TP53 alterations∗ |
| ≥20% | AML with mutated TP53 | Any somatic TP53 mutation (VAF > 10%) |
CK, complex karyotype.
Characterized by ≥2 TP53 mutations or a single TP53 mutation with (1) concurrent evidence of TP53 copy loss (17p deletion on cytogenetics; or VAF of >50%) or (2) copy-neutral loss of heterozygosity.